Your browser doesn't support javascript.
loading
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.
Giuffrida, Lauren; Sek, Kevin; Henderson, Melissa A; House, Imran G; Lai, Junyun; Chen, Amanda X Y; Todd, Kirsten L; Petley, Emma V; Mardiana, Sherly; Todorovski, Izabela; Gruber, Emily; Kelly, Madison J; Solomon, Benjamin J; Vervoort, Stephin J; Johnstone, Ricky W; Parish, Ian A; Neeson, Paul J; Kats, Lev M; Darcy, Phillip K; Beavis, Paul A.
Afiliación
  • Giuffrida L; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Sek K; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Henderson MA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • House IG; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Lai J; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Chen AXY; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Todd KL; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Petley EV; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Mardiana S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Todorovski I; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Gruber E; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Kelly MJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Solomon BJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Vervoort SJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Johnstone RW; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Parish IA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Neeson PJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Kats LM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Darcy PK; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Pathology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Immun
  • Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: paul.beavis@petermac.org.
Mol Ther ; 28(11): 2379-2393, 2020 11 04.
Article en En | MEDLINE | ID: mdl-32735774
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Interleucina-15 / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Etiology_studies / Guideline Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Interleucina-15 / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Etiology_studies / Guideline Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article